首页> 美国卫生研究院文献>MedChemComm >Pyrazolobenzothiazine-based carbothioamides as new structural leads for the inhibition of monoamine oxidases: design synthesis in vitro bioevaluation and molecular docking studies
【2h】

Pyrazolobenzothiazine-based carbothioamides as new structural leads for the inhibition of monoamine oxidases: design synthesis in vitro bioevaluation and molecular docking studies

机译:基于吡唑并苯并噻嗪的碳硫酰胺类化合物可抑制单胺氧化酶:设计合成体外生物评估和分子对接研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Two new series of pyrazolobenzothiazine-based carbothioamides (>3a–o and >4a–o) were synthesized using saccharin as the starting material. The synthesized derivatives were investigated for their ability to inhibit monoamine oxidases (MAO). Compound >3b was found to be a very potent MAO-A inhibitor with an IC50 value of 0.003 ± 0.0007 μM, while compound >4d was the most effective inhibitor of MAO-B having an IC50 value of 0.02 ± 0.001 μM. Molecular docking studies were performed to identify the probable binding modes in the active site of the monoamine oxidase enzymes. The synthetic and computational investigations in the current work suggested that these newly identified inhibitors may serve as a powerful starting point for the exploration and optimization of potential therapeutic agents targeting Parkinson's disease.
机译:以糖精为起始原料合成了两个新的基于吡唑并苯并噻嗪的碳硫酰胺(> 3a–o 和> 4a–o )。研究了合成衍生物抑制单胺氧化酶(MAO)的能力。发现化合物> 3b 是一种非常有效的MAO-A抑制剂,IC50值为0.003±0.0007μM,而化合物> 4d 是最有效的MAO-B抑制剂,具有IC50值为0.02±0.001μM。进行了分子对接研究以鉴定单胺氧化酶酶活性位点中可能的结合模式。当前工作中的合成和计算研究表明,这些新发现的抑制剂可作为探索和优化针对帕金森氏病的潜在治疗剂的有力起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号